BioNTech Total Liab vs Net Working Capital Analysis

BNTX Stock  USD 113.51  0.43  0.38%   
BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Total Liab and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Total Liab vs Net Working Capital

Total Liab vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Total Liab account and Net Working Capital. At this time, the significance of the direction appears to have very strong relationship.
The correlation between BioNTech's Total Liab and Net Working Capital is 0.86. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Total Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of BioNTech SE are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Total Liab i.e., BioNTech's Total Liab and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.86
Relationship DirectionPositive 
Relationship StrengthStrong

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Working Capital

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, BioNTech's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.21 in 2024, whereas Tax Provision is likely to drop slightly above 243 M in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense5.4M18.9M7.9M7.5M
Depreciation And Amortization78.2M121.1M183.4M192.6M

BioNTech fundamental ratios Correlations

0.760.870.851.00.980.62-0.930.990.940.940.880.740.940.680.820.640.760.620.870.810.860.750.971.00.14
0.760.860.880.730.770.76-0.580.680.730.580.590.390.570.770.530.820.430.570.870.750.890.40.740.760.56
0.870.860.970.850.810.45-0.770.830.720.770.570.340.70.860.470.670.370.490.970.630.970.360.760.90.2
0.850.880.970.820.780.46-0.680.790.70.670.560.340.630.940.470.670.380.551.00.571.00.360.750.880.14
1.00.730.850.820.980.62-0.951.00.950.950.90.760.950.640.830.630.780.610.850.810.840.780.970.990.13
0.980.770.810.780.980.75-0.930.980.980.940.940.810.960.570.880.690.820.640.80.90.80.820.990.970.27
0.620.760.450.460.620.75-0.530.60.80.550.790.720.630.260.790.690.740.620.460.920.490.720.770.590.74
-0.93-0.58-0.77-0.68-0.95-0.93-0.53-0.95-0.88-1.0-0.86-0.72-0.98-0.43-0.78-0.55-0.72-0.49-0.71-0.8-0.69-0.74-0.91-0.92-0.13
0.990.680.830.791.00.980.6-0.950.950.960.910.780.970.60.850.590.80.620.820.80.810.80.970.990.09
0.940.730.720.70.950.980.8-0.880.950.90.980.880.940.490.940.680.90.70.730.910.730.890.990.920.28
0.940.580.770.670.950.940.55-1.00.960.90.870.740.980.440.80.550.750.490.710.810.680.760.920.930.14
0.880.590.570.560.90.940.79-0.860.910.980.870.960.940.320.990.570.970.70.60.890.590.970.960.850.24
0.740.390.340.340.760.810.72-0.720.780.880.740.960.850.120.990.391.00.70.390.790.391.00.860.690.14
0.940.570.70.630.950.960.63-0.980.970.940.980.940.850.390.890.550.850.580.670.850.650.860.960.920.15
0.680.770.860.940.640.570.26-0.430.60.490.440.320.120.390.240.510.160.360.910.320.920.140.540.720.0
0.820.530.470.470.830.880.79-0.780.850.940.80.990.990.890.240.490.990.730.510.860.510.990.920.780.24
0.640.820.670.670.630.690.69-0.550.590.680.550.570.390.550.510.490.420.350.660.660.670.40.670.630.44
0.760.430.370.380.780.820.74-0.720.80.90.750.971.00.850.160.990.420.720.430.80.431.00.870.710.16
0.620.570.490.550.610.640.62-0.490.620.70.490.70.70.580.360.730.350.720.60.630.610.70.680.60.23
0.870.870.971.00.850.80.46-0.710.820.730.710.60.390.670.910.510.660.430.60.591.00.410.770.90.12
0.810.750.630.570.810.90.92-0.80.80.910.810.890.790.850.320.860.660.80.630.590.60.790.90.780.63
0.860.890.971.00.840.80.49-0.690.810.730.680.590.390.650.920.510.670.430.611.00.60.410.770.890.15
0.750.40.360.360.780.820.72-0.740.80.890.760.971.00.860.140.990.41.00.70.410.790.410.870.710.14
0.970.740.760.750.970.990.77-0.910.970.990.920.960.860.960.540.920.670.870.680.770.90.770.870.950.25
1.00.760.90.880.990.970.59-0.920.990.920.930.850.690.920.720.780.630.710.60.90.780.890.710.950.12
0.140.560.20.140.130.270.74-0.130.090.280.140.240.140.150.00.240.440.160.230.120.630.150.140.250.12
Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets797.6M2.3B15.8B23.3B23.0B24.2B
Short Long Term Debt Total76.5M240.2M301.5M212.2M219.1M162.4M
Other Current Liab16.4M487.6M1.6B2.1B1.2B751.8M
Total Current Liabilities138.1M606.0M3.5B3.0B2.1B1.3B
Total Stockholder Equity493.5M1.4B11.9B20.1B20.2B21.3B
Other Liab205.6M97.1M109.7M283.9M326.5M166.9M
Net Tangible Assets179.6M406.5M1.2B11.7B13.5B14.1B
Property Plant And Equipment Net148.1M326.0M520.4M821.1M971.6M1.0B
Current Deferred Revenue93.6M391.5M189.1M77.1M353.3M371.0M
Net Debt(450.2M)(970.0M)(1.4B)(13.7B)(11.4B)(10.9B)
Retained Earnings(424.8M)(409.6M)9.9B18.8B19.8B20.8B
Accounts Payable20.5M102.3M160M204.1M354M371.7M
Cash519.1M1.2B1.7B13.9B11.7B12.2B
Non Current Assets Total237.5M651.7M758.5M1.4B3.5B3.7B
Non Currrent Assets Other2K1.0M800K6.5M187.1M196.5M
Other Assets2.4M168.2M22.2M249.2M286.6M300.9M
Long Term Debt68.9M231.0M171.6M176.2M191M116.1M
Cash And Short Term Investments520.8M1.3B2.1B14.1B16.5B17.4B
Net Receivables20.2M166.4M12.4B7.1B2.2B3.0B
Good Will3.0M53.7M57.8M61.2M362.5M380.6M
Common Stock Total Equity166.8M193.3M232.3M246.3M283.3M185.2M
Common Stock Shares Outstanding211.5M248.5M259.7M249.8M242.7M229.1M
Short Term Investments1.7M137.2M381.6M189.4M4.9B5.1B
Liabilities And Stockholders Equity797.6M2.3B15.8B23.3B23.0B24.2B
Non Current Liabilities Total166.0M340.8M455.5M272.9M689.9M378.2M
Inventory11.7M64.1M502.5M439.6M357.7M190.9M
Other Current Assets1.2M392.6M113.8M272.3M460M483M
Other Stockholder Equity(5.5M)1.8B(3.8M)(5.3M)(10.8M)(10.3M)
Total Liab304.2M946.8M3.9B3.2B2.8B1.7B
Property Plant And Equipment Gross148.1M326.0M594.6M821.1M1.2B1.2B
Total Current Assets560.2M1.7B15.1B21.9B19.5B20.5B
Accumulated Other Comprehensive Income691.5M25.5M1.8B979.3M244.8M232.6M
Short Term Debt7.6M15.2M129.9M36M56.2M37.6M
Intangible Assets86.5M109.8M144.6M158.5M781.7M820.8M
Common Stock232.3M246.3M246.3M248.6M285.9M218.0M
Property Plant Equipment116.0M148.1M326.0M520.4M598.5M628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.